Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients

2011; Instituto Oswaldo Cruz, Ministério da Saúde; Volume: 106; Issue: 6 Linguagem: Inglês

10.1590/s0074-02762011000600011

ISSN

1678-8060

Autores

Raquel Lima de Figueiredo Teixeira, Renata Gomes Morato, Pedro Hernán Cabello, Ligia Mayumi Kitada Muniz, Adriana da Silva Rezende Moreira, Afrânio Lineu Kritski, Fernanda Carvalho de Queiroz Mello, Philip Noël Suffys, Antônio Basílio de Miranda, Adalberto Rezende Santos,

Tópico(s)

Drug Transport and Resistance Mechanisms

Resumo

Isoniazid (INH), one of the most important drugs used in antituberculosis (anti-TB) treatment, is also the major drug involved in hepatotoxicity. Differences in INH-induced toxicity have been attributed to genetic variability at several loci, such as NAT2, CYP2E1, GSTM1 and GSTT1, that code for drug-metabolising enzymes. Our goal was to examine the polymorphisms in these enzymes as susceptibility factors to anti-TB drug-induced hepatitis in Brazilian individuals. In a case-control design, 167 unrelated active tuberculosis patients from the University Hospital of the Federal University of Rio de Janeiro, Brazil, were enrolled in this study. Patients with a history of anti-TB drug-induced acute hepatitis (cases with an increase to 3 times the upper limit of normal serum transaminases and symptoms of hepatitis) and patients with no evidence of anti-TB hepatic side effects (controls) were genotyped for NAT2, CYP2E1, GSTM1 and GSTT1 polymorphisms. Slow acetylators had a higher incidence of hepatitis than intermediate/rapid acetylators [22% (18/82) vs. 9.8% (6/61), odds ratio (OR), 2.86, 95% confidence interval (CI), 1.06-7.68, p = 0.04). Logistic regression showed that slow acetylation status was the only independent risk factor (OR 3.59, 95% CI, 2.53-4.64, p = 0.02) for the occurrence of anti-TB drug-induced hepatitis during anti-TB treatment with INH-containing schemes in Brazilian individuals.

Referência(s)